F-Prime Capital

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it has a strong legacy rooted in Fidelity Investments, which has been a significant player in asset management since 1946. F Prime focuses on early-stage investments in North America and Europe, primarily in the healthcare, life sciences, technology, therapeutics, fashion, medtech, and health information technology sectors. The firm operates several funds, including those dedicated to healthcare, oncology, life sciences, and health technology services. F Prime Capital Partners emphasizes supporting entrepreneurs without the pressure of external fundraising, allowing them to concentrate on identifying and nurturing promising companies.

Abdul Abdirahman

Principal

Jessica Alston

Partner

Nikhil Ananth

Senior Associate

Hannah Arnold

Principal

Raj Basak

Associate

Thomas R. Beck

Executive Partner

Sam Bisbee

Venture Partner

Eric Blatte

Venture Partner

Carl Byers

Partner

Kevin Chu

Principal

Lucille Conroy

Senior Associate

Brett Cook

Partner

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Investor

Benjamin Gorman

Venture Partner

Ben Gorman

Principal

David Jegen

Managing Partner

Stephen Knight

President and Managing Partner

Sarah Lamont

Senior Associate

Erica Lee

Senior Associate

Connie Li

Associate

Jon Lim

Partner

Jonathan P. Lim

Managing Partner

Jiang Lin

Principal

Muzammil Mansuri

Venture Partner

Julia McDowell

Venture Partner

Betsy Mulé

Senior Associate

Alex Pasteur

Partner

Ketan Patel

Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

Brett J. Rome

Venture Partner

Steve Schultz

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi

Associate

Nihal Sinha

Partner

Anastasiya Sybirna

Senior Associate

Martin Taylor

Senior Associate

Gaurav Tuli

Partner

Jennifer Uhrig

Senior Managing Director

Bala Varadhan

Principal

Robert Weisskoff

Partner

Stacie Weninger

Executive Director

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Principal

Fang Yu

Partner

Michael Zheng

Venture Partner

Past deals in Health Diagnostics

1upHealth

Series C in 2023
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

SpectrumAi

Seed Round in 2022
SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. The company collaborates with clinical leaders in ABA therapy, parents, and payers to modernize treatment approaches. SpectrumAi's healthcare technology offers objective data and meaningful insights, providing actionable guidance that empowers patients to work towards independent living, meaningful relationships, lifelong vocation, and self-advocacy. Through its innovative solutions, SpectrumAi aims to provide alternatives for life-changing therapies, ultimately improving outcomes for individuals on the autism spectrum.

Proof Diagnostics

Series A in 2022
Proof Diagnostics focuses on developing CRISPR-based molecular tests for the detection of COVID-19. The company aims to empower communities by providing rapid diagnostic kits that enable medical professionals to effectively test patients for coronavirus infections. By leveraging advanced genetic technologies, Proof Diagnostics contributes to improved health outcomes and better management of infectious diseases.

Doceree

Series A in 2022
Doceree Inc operates a programmatic physician engagement and advertising platform that facilitates targeted advertising for healthcare professionals. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, the company provides access to exclusive physician-only platforms. Utilizing artificial intelligence, data segmentation, and analytics, Doceree enables advertisers to identify and reach healthcare professionals across various digital channels, including physician networking sites, medical journals, and telemedicine platforms. The company's services cater to a diverse clientele, including media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals, allowing them to deliver accurate and transparent messaging at scale.

Eleos Health

Series A in 2022
Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

AmplifyMD

Series A in 2022
AmplifyMD is a telemedicine platform connecting over 3,300 medical institutions with a lack of specialty access, often in rural or small regions to a network of leading specialists.AmplifyMD provides both the clinical team as well as the software to streamline and automate virtual care delivery and billing workflows and integrates seamlessly with hospitals' existing EHRs.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Patina

Series A in 2021
We believe everyone should have the opportunity to live their best lives and age with dignity. That’s why we’re reinventing primary care with an approach designed to profoundly improve the healthcare and aging experience for older adults and their loved ones.

RareCyte

Series G in 2021
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Oviva

Series C in 2021
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Embark

Series B in 2021
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Adela

Series A in 2021
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Zus Health

Series A in 2021
Zus Health is a developer of a healthcare data platform designed to enhance digital health by facilitating the creation of customized technologies and services. The platform connects both health and non-health information, offering a comprehensive view of patients while allowing for the sharing of clinical and non-clinical data without the need for shared applications. By removing traditional barriers in healthcare technology development, Zus Health empowers healthcare professionals to develop solutions that are more affordable and tailored to individual needs, ultimately aiming to improve the overall healthcare experience.

Protenus

Series D in 2021
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Pediatrix Therapeutics

Series A in 2021
Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

1upHealth

Series B in 2021
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

Firefly Health

Series B in 2021
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

Genomics

Venture Round in 2021
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Cohort

Series B in 2021
Cohort, Inc. specializes in developing software that enhances chronic care management and clinical trials. The company's clinical AI and natural language processing technology analyzes electronic health records (EHR), extracting insights from diagnostics, medications, and clinical notes to provide tailored context for patients and their conditions. Cohort's platform streamlines the identification and enrollment of eligible patients, generates care plans automatically, and facilitates compliance and billing processes. By offering these solutions, Cohort enables primary care providers to improve the scale and efficiency of their chronic care management programs while also enhancing the identification and enrollment process for clinical trials. The company is headquartered in New York, with an additional office in San Francisco.

Hurdle

Seed Round in 2021
Providing self-care support and mental health service to Black men

Atalanta Therapeutics

Series A in 2021
Atalanta Therapeutics is a biotechnology company focused on developing innovative treatment options for neurodegenerative diseases through its proprietary RNA interference platform. The company aims to create therapeutics that target various conditions, including Huntington's disease by specifically targeting the HTT gene. By addressing the underlying causes of these diseases, Atalanta Therapeutics seeks to provide clinicians with effective strategies to halt disease progression and improve patient outcomes.

WellAir

Venture Round in 2020
WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.

PatientPing

Series C in 2020
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

Devoted

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Devoted

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Iora Health

Series F in 2020
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

WelbeHealth

Series C in 2020
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Oviva

Series B in 2020
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Medbanks

Series D in 2019
Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.

Wellframe

Series C in 2019
Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

Firefly Health

Series A in 2019
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Protenus

Series C in 2019
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Buoy Health

Series B in 2019
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Quartet Health

Series D in 2019
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

LunaPBC

Venture Round in 2019
LunaPBC, Inc. operates a community-owned platform focused on health and DNA research. The company offers LunaDNA, a database that facilitates the sharing of health and genetic data for medical research. This platform supports health research initiatives by both non-profit and for-profit organizations, contributing to medical discoveries. LunaPBC operates as a Public Benefit Corporation, emphasizing community welfare by allowing individuals to share their health data, which in turn drives research and innovation. Additionally, members of the platform have the opportunity to share in the earnings derived from medical advancements, promoting a sense of shared ownership and benefit within the community. Founded in 2017 and based in San Diego, California, LunaPBC aims to advance genomic and medical research while prioritizing the interests of its contributors.

LunaDNA

Venture Round in 2019
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.

Embark

Series A in 2019
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

ABK Biomedical

Series B in 2019
ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.

Artemis Health

Series C in 2019
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

TreeENT

Series A in 2019
TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.

Singular Genomics

Venture Round in 2019
Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Medbanks

Series D in 2018
Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.

Genomics

Series B in 2018
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Avidity Biosciences

Series B in 2018
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Devoted

Series B in 2018
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Modis Therapeutics

Series A in 2018
Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.

Xilio Therapeutics

Series A in 2018
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

WelbeHealth

Series B in 2018
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Iora Health

Series E in 2018
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Hua Medicine

Series D in 2018
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Protenus

Series B in 2018
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Quartet Health

Series C in 2018
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Oviva

Series A in 2017
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Devoted

Series A in 2017
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Stride Health

Series B in 2017
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Artemis Health

Series B in 2017
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

Buoy Health

Series A in 2017
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Protenus

Series A in 2017
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Wellframe

Series B in 2017
Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

Medwell Ventures

Series B in 2017
Medwell Ventures Private Limited is a provider of specialty home healthcare services in India, focusing on a range of therapeutic areas. Established in 2014 and headquartered in Bengaluru, the company offers a variety of wellness and care programs, including preventive screening, palliative care, and bedside nursing. Its services encompass 24×7 medical support, physician consultations, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, and pharmacy support. By integrating different healthcare delivery channels, Medwell Ventures aims to enhance the accessibility and personalization of medical treatment for patients with chronic diseases and diverse health profiles.

Celes Care

Seed Round in 2017
Celes Care is India’s first Online Health Clinic for Women. We offer doctor consultation services on Pregnancy Care, Nutrition, Wellness & General Health. Our online consultation service is highly affordable and delivered by our expert women doctors who are compassionate and care for your health. We connect you with our doctors within a minute.

WelbeHealth

Series A in 2017
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Cytek

Series B in 2017
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.

Core Diagnostics

Series B in 2016
Core Diagnostics Private Limited is a clinical laboratory based in Gurugram, India, established in 2012. The company specializes in next-generation diagnostics aimed at disease stratification and therapy selection. By employing advanced testing techniques, Core Diagnostics seeks to provide comprehensive diagnostic solutions and become a leading provider of high-end diagnostic services in the region.

Iora Health

Series D in 2016
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Xilio Therapeutics

Series A in 2016
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Denali Therapeutics

Series B in 2016
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

US HealthVest

Series B in 2016
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Hua Medicine

Series C in 2016
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Quartet Health

Series B in 2016
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Cytek

Venture Round in 2016
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.

Haici Technology

Series A in 2016
Haiui Health Technology is a mobile platform for hospitals to connect patients, optimise hospital visits and streamline admin workflow.

Cipla Health

Venture Round in 2016
Cipla Health focuses on developing and commercialising products in the consumer healthcare .

WelbeHealth

Seed Round in 2015
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

PatientPing

Series A in 2015
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

Proteostasis Therapeutics

Series B in 2015
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.

Medwell Ventures

Series A in 2015
Medwell Ventures Private Limited is a provider of specialty home healthcare services in India, focusing on a range of therapeutic areas. Established in 2014 and headquartered in Bengaluru, the company offers a variety of wellness and care programs, including preventive screening, palliative care, and bedside nursing. Its services encompass 24×7 medical support, physician consultations, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, and pharmacy support. By integrating different healthcare delivery channels, Medwell Ventures aims to enhance the accessibility and personalization of medical treatment for patients with chronic diseases and diverse health profiles.

Stride Health

Series A in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Denali Therapeutics

Series A in 2015
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Precision BioSciences

Series A in 2015
Precision BioSciences, Inc. is a biotechnology company that specializes in genome editing, utilizing its proprietary ARCUS platform to develop therapeutic and food products. The Therapeutic segment focuses on creating allogeneic CAR T immunotherapies aimed at treating various cancers, including acute lymphoblastic leukemia and multiple myeloma, with several candidates currently in clinical trials. Notable product candidates include PBCAR0191, targeting CD19, and PBCAR269A, targeting BCMA. Additionally, the company is engaged in in vivo gene correction and has collaborations for developing treatments for chronic Hepatitis B. The Food segment aims to innovate in food and nutrition products. Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences is committed to translating advanced genome editing technology into impactful medical and agricultural solutions.

Dimension Therapeutics

Series B in 2015
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Medbanks

Series A in 2015
Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.

Quartet Health

Series A in 2015
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Iora Health

Series C in 2015
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Stride Health

Seed Round in 2015
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Cytek

Seed Round in 2015
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.

Novaerus

Venture Round in 2014
Novaerus's mission is to improve the business and quality of care through the application of airborne pathogen control technology. Novaerus believe that the preventative approach is the proper path to improved business and quality results in skilled nursing and assisted living facilities. Traditionally, important steps have been taken to clean hands and surfaces. Protocols exist on hand washing, surface cleaning and disinfectant and even isolation used as a tactic to prevent pathogens. When used in conjunction with these traditional methods, the Novaerus technology can go beyond just scrubbing hands and surfaces.

Dimension Therapeutics

Series A in 2014
Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

WellAir

Venture Round in 2014
WellAir Group Limited specializes in designing and manufacturing portable air disinfection units, HVAC air purification devices, and sensors aimed at improving indoor air quality. The company's products effectively remove airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. WellAir markets its offerings under the Novaerus and Plasma-Air brand names, serving a diverse clientele that includes hospitals, senior living facilities, schools, casinos, railway stations, residences, and industrial facilities. Its Novaerus Portables are medical-grade air disinfection units that deactivate airborne pathogens while neutralizing volatile organic compounds. The Plasma-Air HVAC systems utilize plasma-generated bipolar ionization to diminish particulate matter, odors, viruses, and bacteria. Additionally, WellAir manufactures sensors and provides a web-based monitoring portal that tracks outdoor air pollution, flu levels, pollen counts, and weather conditions. Founded in 2012 and based in Dublin, Ireland, WellAir is dedicated to creating safe indoor environments for the health and well-being of individuals.

Iora Health

Series B in 2013
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

US HealthVest

Series A in 2013
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Lumere

Seed Round in 2012
Lumere, Inc. is a Chicago-based organization that offers a cloud-based platform designed to assist hospitals and healthcare providers in reducing clinical variation and minimizing costs related to medical devices and pharmaceuticals. The company provides a suite of tools, including Product Introduction Management, which refines the device vetting process using clinical evidence and industry best practices. Its Category Optimization service integrates clinical insights and market intelligence to identify savings opportunities within health systems. Additionally, Lumere's Variation Management analyzes procedural utilization data to evaluate how medical devices are used by physicians, while its Utilization Management combines relevant clinical information with prescriber patterns to optimize drug spending. The organization also offers physician advisory services to foster collaboration between clinicians and hospital leadership. Lumere was incorporated in 2012 and operates as a subsidiary of Global Healthcare Exchange, LLC.

Hua Medicine

Series A in 2011
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Iora Health

Venture Round in 2011
Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Accuri Cytometers

Series E in 2010
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.